
Opinion|Videos|June 24, 2024
Selecting Optimal Treatment in BCG-Unresponsive NMIBC
A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia
5












